COMMUNIQUÉS West-GlobeNewswire

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
08/01/2026
ALK ( ALKB:DC / OMX: ALK B ) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco on [...]
Vystar Corp. Submits Binding Letter of Intent to Acquire Stake in GoPaid.com LLC and Form Strategic Partnership with Capital R3alm to Launch R3alm Oracle and R3alm Collectibles
08/01/2026
Worcester, Massachusetts, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST ), a diversified innovation company with operations spanning eco-friendly products and collectibles monetization, today [...]
Easy Environmental Solutions Enters 2026 With Accelerated Global Momentum and a Clear Path to Scale
08/01/2026
Company surpasses 2025 international development targets and advances toward multi-continent deployment of disruptive integrated soil and water technologies MANKATO, Minn., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Easy [...]
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
08/01/2026
Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation Award Expands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free [...]
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
08/01/2026
GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional financial support [...]
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
08/01/2026
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next- [...]
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
08/01/2026
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE [...]
Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer
08/01/2026
KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform specializing in predictive, [...]
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
08/01/2026
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with [...]
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
08/01/2026
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
R1 Launches Phare Audit, the AI-Native Solution to Capture Full Reimbursement, Reduce Revenue Leakage and Improve Quality
08/01/2026
Phare Audit Uses Proprietary Agentic AI to Maximize Earned Reimbursement, Enhancing R1’s Industry-Leading DRG-V with Full Auditability CHICAGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in [...]
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials
08/01/2026
FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026 HREC Approval Received for Next-Generation Bispecific NAV-242 to Initiate First-in-Human Phase 1 Program with Ph1a [...]
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
08/01/2026
Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative [...]
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
08/01/2026
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also [...]
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
08/01/2026
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 [...]
RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026
08/01/2026
MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today provided a corporate [...]
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
08/01/2026
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. ( [...]
ORYZON to Participate in Upcoming Events in January
08/01/2026
MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its [...]
AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)
08/01/2026
Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United States Therapy granted United States Food and Drug Administration (FDA) Fast Track and [...]

Pages